{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:16:06Z","timestamp":1794975366301,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Department of Health & Human Services | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["R01007480"],"award-info":[{"award-number":["R01007480"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-63863-8","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:04:08Z","timestamp":1759914248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Selective HLA knockdown and PD-L1 expression prevent allogeneic CAR-NK cell rejection and enhance safety and anti-tumor responses in xenograft mice"],"prefix":"10.1038","volume":"16","author":[{"given":"Fuguo","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubin","family":"Tarannum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7170-2403","authenticated-orcid":false,"given":"Yingjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8102-3815","authenticated-orcid":false,"given":"Yiming J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0971-7940","authenticated-orcid":false,"given":"James Dongjoo","family":"Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-682X","authenticated-orcid":false,"given":"Kewen","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maily","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanhlinh","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5257-6775","authenticated-orcid":false,"given":"Shaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Kassim","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9077-4736","authenticated-orcid":false,"given":"Rizwan","family":"Romee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-6154","authenticated-orcid":false,"given":"Jianzhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"63863_CR1","doi-asserted-by":"publisher","unstructured":"Xie, G. et al. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine 59 https:\/\/doi.org\/10.1016\/j.ebiom.2020.102975 (2020).","DOI":"10.1016\/j.ebiom.2020.102975"},{"key":"63863_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"63863_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier, E. et al. Natural killer cell therapies. Nature 626, 727\u2013736 (2024).","journal-title":"Nature"},{"key":"63863_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/hum.2017.254","volume":"29","author":"U K\u00f6hl","year":"2018","unstructured":"K\u00f6hl, U., Arsenieva, S., Holzinger, A., Abken, H. & CAR, T. Cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum. Gene Ther. 29, 559\u2013568 (2018).","journal-title":"Hum. Gene Ther."},{"key":"63863_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski, T. J., Biederst\u00e4dt, A. & Rezvani, K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat. Rev. Cancer 22, 557\u2013575 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"63863_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. & Schumacher, T. N. T cell dysfunction in cancer. Cancer Cell 33, 547\u2013562 (2018).","journal-title":"Cancer Cell"},{"key":"63863_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185\u2013199 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"63863_CR8","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","volume":"13","author":"S Jo","year":"2022","unstructured":"Jo, S., et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nat. Commun. 13, 3453 (2022).","journal-title":"Nat. Commun."},{"key":"63863_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2326-6066.CIR-23-0679","volume":"12","author":"\u00c9 Degagn\u00e9","year":"2024","unstructured":"Degagn\u00e9, \u00c9., et al. High-specificity CRISPR-mediated genome engineering in anti-BCMA allogeneic CAR T cells suppresses allograft rejection in preclinical models. Cancer Immunol. Res. 12, 462\u2013477 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"63863_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1161\/CIRCRESAHA.114.305495","volume":"116","author":"V Karantalis","year":"2015","unstructured":"Karantalis, V., Schulman, I. H., Balkan, W. & Hare, J. M. Allogeneic cell therapy: a new paradigm in therapeutics. Circ. Res. 116, 12\u201315 (2015).","journal-title":"Circ. Res."},{"key":"63863_CR11","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051\u20133057 (2005).","journal-title":"Blood"},{"key":"63863_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85\u2013100 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"63863_CR13","doi-asserted-by":"publisher","unstructured":"Reindl, L. M. et al. Immunotherapy with NK cells: recent developments in gene modification open up new avenues. OncoImmunology 9 https:\/\/doi.org\/10.1080\/2162402X.2020.1777651 (2020).","DOI":"10.1080\/2162402X.2020.1777651"},{"key":"63863_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"63863_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"63863_CR16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41581-018-0039-x","volume":"14","author":"RA Montgomery","year":"2018","unstructured":"Montgomery, R. A., Tatapudi, V. S., Leffell, M. S. & Zachary, A. A. HLA in transplantation. Nat. Rev. Nephrol. 14, 558\u2013570 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"63863_CR17","doi-asserted-by":"publisher","unstructured":"Zhao, W. et al. iScience strategies for genetically engineering hypoimmunogenic universal pluripotent stem cells. https:\/\/doi.org\/10.1016\/j.isci.","DOI":"10.1016\/j.isci"},{"key":"63863_CR18","doi-asserted-by":"publisher","first-page":"e2320879121","DOI":"10.1073\/pnas.2320879121","volume":"121","author":"J Lee","year":"2024","unstructured":"Lee, J., Oldham, M. L., Manon, V. & Chen, J. Principles of peptide selection by the transporter associated with antigen processing. Proc. Natl. Acad. Sci. USA 121, e2320879121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"63863_CR19","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1038\/s41467-023-40736-6","volume":"14","author":"L Li","year":"2023","unstructured":"Li, L., Peng, X., Batliwala, M. & Bouvier, M. Crystal structures of MHC class I complexes reveal the elusive intermediate conformations explored during peptide editing. Nat. Commun. 14, 5020 (2023).","journal-title":"Nat. Commun."},{"key":"63863_CR20","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nri3084","volume":"11","author":"J Neefjes","year":"2011","unstructured":"Neefjes, J., Jongsma, M. L. M., Paul, P. & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11, 823\u2013836 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"63863_CR21","unstructured":"Horowitz, A. et al. I M M U N O L O G Y Genetic and Environmental Determinants of Human NK Cell Diversity Revealed by Mass Cytometry. https:\/\/www.science.org."},{"key":"63863_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","volume":"25","author":"N Anfossi","year":"2006","unstructured":"Anfossi, N. et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25, 331\u2013342 (2006).","journal-title":"Immunity"},{"key":"63863_CR23","doi-asserted-by":"crossref","unstructured":"Val\u00e9 S-G\u00f3 Mez, M., Reyburn, H. T., Erskine, R. A., L\u00f3 Pez-Botet, M. & Strominger, J. L. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94\/NKG2-A and the activating receptor CD94\/NKG2-C to HLA-E. EMBO J. 18 https:\/\/www.embopress.org (1999).","DOI":"10.1093\/emboj\/18.15.4250"},{"key":"63863_CR24","doi-asserted-by":"crossref","unstructured":"Kaiser, B. K., Pizarro, J. C., Kerns, J. & Strong, R. K. Structural Basis for NKG2A\/CD94 Recognition of HLA-E. www.pnas.org\/cgi\/content\/full\/ (2008).","DOI":"10.1073\/pnas.0802736105"},{"key":"63863_CR25","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He, X. & Xu, C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 30, 660\u2013669 (2020).","journal-title":"Cell Res."},{"key":"63863_CR26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson, D. B., Nebhan, C. A., Moslehi, J. J. & Balko, J. M. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat. Rev. Clin. Oncol. 19, 254\u2013267 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"63863_CR27","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1470-2045(22)00395-3","volume":"23","author":"C Lebb\u00e9","year":"2022","unstructured":"Lebb\u00e9, C., Biard, L., Delyon, J. & Zuber, J. Managing immune checkpoint inhibition in transplant recipients. Lancet Oncol. 23, 969\u2013971 (2022).","journal-title":"Lancet Oncol."},{"key":"63863_CR28","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41586-020-2631-z","volume":"586","author":"E Yoshihara","year":"2020","unstructured":"Yoshihara, E. et al. Immune-evasive human islet-like organoids ameliorate diabetes. Nature 586, 606\u2013611 (2020).","journal-title":"Nature"},{"key":"63863_CR29","doi-asserted-by":"crossref","unstructured":"Hu, X. et al. Human Hypoimmune Primary Pancreatic Islets Avoid Rejection and Autoimmunity and Alleviate Diabetes in Allogeneic Humanized Mice. https:\/\/www.science.org (2023).","DOI":"10.1126\/scitranslmed.adg5794"},{"key":"63863_CR30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","volume":"35","author":"GG Gornalusse","year":"2017","unstructured":"Gornalusse, G. G. et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat. Biotechnol. 35, 765\u2013772 (2017).","journal-title":"Nat. Biotechnol."},{"key":"63863_CR31","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/CIRCULATIONAHA.107.741025","volume":"117","author":"J Yang","year":"2008","unstructured":"Yang, J. et al. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation 117, 660\u2013669 (2008).","journal-title":"Circulation"},{"key":"63863_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41587-023-01784-x","volume":"42","author":"X Hu","year":"2024","unstructured":"Hu, X. et al. Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques. Nat. Biotechnol. 42, 413\u2013423 (2024).","journal-title":"Nat. Biotechnol."},{"key":"63863_CR33","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1158\/2159-8290.CD-18-1259","volume":"9","author":"W Dong","year":"2019","unstructured":"Dong, W. et al. The mechanism of anti\u2013PD-L1 antibody efficacy against PD-L1\u2013negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. Cancer Discov. 9, 1422\u20131437 (2019).","journal-title":"Cancer Discov."},{"key":"63863_CR34","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1158\/2326-6066.CIR-23-0324","volume":"12","author":"T Lu","year":"2024","unstructured":"Lu, T. et al. Preclinical evaluation of off-the-shelf PD-L1+ human natural killer cells secreting IL15 to treat non-small cell lung cancer. Cancer Immunol. Res 12, 731\u2013743 (2024).","journal-title":"Cancer Immunol. Res"},{"key":"63863_CR35","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731\u20131743.e13 (2018).","journal-title":"Cell"},{"key":"63863_CR36","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41588-021-00889-w","volume":"53","author":"M Sheffer","year":"2021","unstructured":"Sheffer, M. et al. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nat. Genet. 53, 1196\u20131206 (2021).","journal-title":"Nat. Genet."},{"key":"63863_CR37","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","volume":"52","author":"MEW Logtenberg","year":"2020","unstructured":"Logtenberg, M. E. W., Scheeren, F. A. & Schumacher, T. N. The CD47-SIRP\u03b1 immune checkpoint. Immunity 52, 742\u2013752 (2020).","journal-title":"Immunity"},{"key":"63863_CR38","doi-asserted-by":"crossref","unstructured":"Braud, V. M. et al. HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C. Nature. 391, 795\u2013799 (1998).","DOI":"10.1038\/35869"},{"key":"63863_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.it.2010.07.003","volume":"31","author":"TH Hansen","year":"2010","unstructured":"Hansen, T. H., Connolly, J. M., Gould, K. G. & Fremont, D. H. Basic and translational applications of engineered MHC class I proteins. Trends Immunol 31, 363\u2013369 (2010).","journal-title":"Trends Immunol"},{"key":"63863_CR40","doi-asserted-by":"publisher","unstructured":"Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. ImmunoTherapy Cancer 6 https:\/\/doi.org\/10.1186\/s40425-018-0343-9 (2018).","DOI":"10.1186\/s40425-018-0343-9"},{"key":"63863_CR41","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","volume":"175","author":"N van Montfoort","year":"2018","unstructured":"van Montfoort, N. et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell 175, 1744\u20131755.e15 (2018).","journal-title":"Cell"},{"key":"63863_CR42","doi-asserted-by":"publisher","first-page":"e20200839","DOI":"10.1084\/jem.20200839","volume":"218","author":"T Deuse","year":"2021","unstructured":"Deuse, T. et al. The SIRP\u03b1-CD47 immune checkpoint in NK cells. J. Exp. Med. 218, e20200839 (2021).","journal-title":"J. Exp. Med."},{"key":"63863_CR43","doi-asserted-by":"publisher","unstructured":"Farhat, M. et al. PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL. Leukemia https:\/\/doi.org\/10.1038\/s41375-024-02271-1 (2024).","DOI":"10.1038\/s41375-024-02271-1"},{"key":"63863_CR44","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1172\/JCI133353","volume":"130","author":"SJ Judge","year":"2020","unstructured":"Judge, S. J. et al. Minimal PD-1 expression in mouse and human NK cells under diverse conditions. J. Clin. Investig. 130, 3051\u20133068 (2020).","journal-title":"J. Clin. Investig."},{"key":"63863_CR45","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.5966\/sctm.2015-0049","volume":"4","author":"D Wang","year":"2015","unstructured":"Wang, D., Quan, Y., Yan, Q., Morales, J. E. & Wetsel, R. A. Targeted disruption of the \u03b2 2-microglobulin gene minimizes the immunogenicity of human embryonic stem cells. Stem Cells Transl. Med. 4, 1234\u20131245 (2015).","journal-title":"Stem Cells Transl. Med."},{"key":"63863_CR46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cr.2016.142","volume":"27","author":"X Liu","year":"2017","unstructured":"Liu, X. et al. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 27, 154\u2013157 (2017).","journal-title":"Cell Res."},{"key":"63863_CR47","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.stem.2014.10.004","volume":"15","author":"PK Mandal","year":"2014","unstructured":"Mandal, P. K. et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR\/Cas9. Cell Stem Cell 15, 643\u2013652 (2014).","journal-title":"Cell Stem Cell"},{"key":"63863_CR48","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/s41587-022-01566-x","volume":"41","author":"PM Bruno","year":"2023","unstructured":"Bruno, P. M. et al. High-throughput, targeted MHC class I immunopeptidomics using a functional genetics screening platform. Nat. Biotechnol. 41, 980\u2013992 (2023).","journal-title":"Nat. Biotechnol."},{"key":"63863_CR49","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1084\/jem.20072525","volume":"205","author":"EJ Petrie","year":"2008","unstructured":"Petrie, E. J. et al. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence. J. Exp. Med. 205, 725\u2013735 (2008).","journal-title":"J. Exp. Med."},{"key":"63863_CR50","doi-asserted-by":"publisher","unstructured":"Hammer, Q. et al. Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell Stem Cell https:\/\/doi.org\/10.1016\/j.stem.2024.06.011 (2024).","DOI":"10.1016\/j.stem.2024.06.011"},{"key":"63863_CR51","doi-asserted-by":"crossref","unstructured":"Coronel, M. M. et al. Immunotherapy via PD-L1-Presenting Biomaterials Leads to Long-Term Islet Graft Survival. https:\/\/www.science.org (2020).","DOI":"10.1126\/sciadv.aba5573"},{"key":"63863_CR52","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","volume":"76","author":"CA Clark","year":"2016","unstructured":"Clark, C. A. et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 76, 6964\u20136974 (2016).","journal-title":"Cancer Res."},{"key":"63863_CR53","doi-asserted-by":"publisher","unstructured":"Romee, R. et al. Cytokine activation induces human memory-like NK cells https:\/\/doi.org\/10.1182\/blood-2012 (2012).","DOI":"10.1182\/blood-2012"},{"key":"63863_CR54","doi-asserted-by":"publisher","unstructured":"Dong, H. et al. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia https:\/\/doi.org\/10.1073\/pnas (2022).","DOI":"10.1073\/pnas"},{"key":"63863_CR55","doi-asserted-by":"crossref","unstructured":"Tarannum, M. et al. CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer. Sci. Adv. 10 https:\/\/www.science.org (2024).","DOI":"10.1126\/sciadv.adn0881"},{"key":"63863_CR56","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/bioinformatics\/bty895","volume":"35","author":"A Zhu","year":"2019","unstructured":"Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-Tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics 35, 2084\u20132092 (2019).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63863-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63863-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63863-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:04:14Z","timestamp":1759914254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63863-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63863"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63863-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C., F.L. and R.R. are named inventors on a patent application based on this work. J.C. and R.R. are co-founders of InnDura Therapeutics. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8809"}}